ALKS

Rating neutralAI Memo

Alkermes

As of 2026-08-07/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-07 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

Planned CEO transition • 2026-08-01

Base target: $53 / p=50% prob

Biggest risk

GAAP profitability weakened materially despite revenue growth, while product concentration, clinical readout risk, regulatory timing, and execution under the new CEO could limit valuation expansion. Recent officer and director open-market sales are an additional monitoring signal, but not evidence of operating deterioration [#SEC-FORM4-2026-08-03].

Invalidation

Break below $40 or thesis failure.

What would change my mind?

Commercial portfolio growth, LUMRYZ contribution, and potential orexin pipeline expansion provide a credible medium-term growth path. Q2 proprietary product revenue was $411.7 million, including $96.6 million from LUMRYZ [#SEC-8K-2026-07-28].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-07

Base target

$53

p=50%

Bull target

$62

p=25%

Bear target

$40

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 commercial growth with mixed earnings quality
ALKS 7290 ADHD data
Alixorexton idiopathic hypersomnia readout

BearKey bullets

CEO transition and execution under the new leadership structure remain untested [#SEC-8K-2026-07-28].
Commercial exposure is concentrated in VIVITROL, ARISTADA, LYBALVI, and LUMRYZ.
GAAP net income declined sharply year over year despite higher revenue and adjusted EBITDA [#SEC-8K-2026-07-28].

WatchKey bullets

Planned CEO transition

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $53 (p=50%)

Target spread vs base: +17% / -25%

Scenario probabilities

Bull Target: $62 (p=25%)Base Target: $53 (p=50%)Bear Target: $40 (p=25%)

Commentary

Primary-source tone is constructive on commercial execution and the orexin pipeline, but the earnings-quality mix is cautious rather than clearly bullish. The packet lacks usable analyst-revision, options, short-interest, employee-sentiment, and social-coverage data; those missing channels are not positive evidence. Overall evidence supports monitoring rather than an aggressive directional thesis.

As of 2026-08-07 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 commercial growth with mixed earnings quality
ALKS 7290 ADHD data
Alixorexton idiopathic hypersomnia readout

Scenarios

Bull Target (Scenario probability)

$62 / p=25% prob

Base Target (Scenario probability)

$53 / p=50% prob

Bear Target (Scenario probability)

$40 / p=25% prob

Analysis 2026-08-07 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-01
Planned CEO transition
Blair Jackson assumed the CEO role on August 1, 2026, while Richard Pops continues as chairman. The transition appears planned, but execution under the new leadership structure remains a monitoring point [#SEC-8K-2026-07-28].
Prob 85.00% • Move 2.00% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

Q2 commercial growth with mixed earnings quality
2026-07-28
Q2 revenue increased to $496.0 million from $390.7 million and adjusted EBITDA rose to $139.2 million from $126.5 million, but GAAP net income fell to $0.5 million from $87.1 million. This supports commercial momentum but limits near-term rerating confidence [#SEC-8K-2026-07-28].
Prob 75% • Move 3% • Priced-in 75%

Long-term Catalysts

Months to a year

ALKS 7290 ADHD data
2026-12-31
Management expects the first ADHD data for ALKS 7290 in the coming months. Positive data could strengthen the orexin 2 receptor portfolio thesis, while a weak or delayed readout would pressure expectations [#SEC-8K-2026-07-28].
Prob 65% • Move 10% • Priced-in 45%
Alixorexton idiopathic hypersomnia readout
2026-12-31
Topline results from the alixorexton phase 2 idiopathic hypersomnia study are expected toward year-end, creating a meaningful but uncertain clinical catalyst [#SEC-8K-2026-07-28].
Prob 65% • Move 12% • Priced-in 45%

Risks

CEO transition and execution under the new leadership structure remain untested [#SEC-8K-2026-07-28].
Commercial exposure is concentrated in VIVITROL, ARISTADA, LYBALVI, and LUMRYZ.
GAAP net income declined sharply year over year despite higher revenue and adjusted EBITDA [#SEC-8K-2026-07-28].
Orexin clinical data could disappoint or be delayed, including ALKS 7290 ADHD data and the alixorexton idiopathic hypersomnia readout [#SEC-8K-2026-07-28].
Recent Form 4 filings show open-market sales by certain officers and a director; this is a monitoring signal only [#SEC-FORM4-2026-08-03].

Peers

Symbol	Summary
LQDA	Same-sector mid-cap biotech candidate, but the packet does not establish sufficient indication or commercial overlap for a tight valuation comparison.
IMVT	Same-sector biotech candidate with limited disclosed comparability; useful only as a broad risk-appetite reference, not a direct operating peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-07

Loading AI feed…

Symbol

Summary

LQDA

Same-sector mid-cap biotech candidate, but the packet does not establish sufficient indication or commercial overlap for a tight valuation comparison.

IMVT

Same-sector biotech candidate with limited disclosed comparability; useful only as a broad risk-appetite reference, not a direct operating peer.